ibrutinib + cytarabine

Ibrutinib + cytarabine is a combination of two pharmaceutical agents used primarily in the treatment of hematologic malignancies. Ibrutinib is an oral small molecule inhibitor that irreversibly binds to Bruton’s tyrosine kinase (BTK), a key enzyme in B-cell receptor signaling pathways. This inhibition disrupts survival and proliferation signals in malignant B cells and is approved for diseases such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. Cytarabine is an antimetabolite chemotherapeutic agent that mimics nucleosides, interfering with DNA synthesis during the S phase of the cell cycle by incorporation into DNA and inhibition of DNA polymerases. The combination has been investigated for acute myeloid leukemia (AML) and other leukemias; preclinical studies suggested potential synergy due to complementary mechanisms—targeting both proliferative signaling (ibrutinib) and DNA synthesis/repair (cytarabine). However, clinical trials have shown limited efficacy for this combination in AML but an acceptable safety profile[1][2][3][5].